Anything is Possible with the Right Approach

Welcome to our investors centre, where you can find official investor focused news, reports and presentations as well as informtion on the markets we address, our company strategy and leadership team. At Creo Medical, we are dedicated to improving patient outcomes by applying Advanced Energy to the emerging field of surgical endoscopy, and our focus is to address significant markets where we can contribute products that make a difference to the lives of patients and serve poorly met needs.

Advisors

Board of directors

Corporate governance

Key strengths

Regulatory updates

Reports and presentations

Rule 26

Share price information

Capital Markets Day 2025

Creo Medical's Capital Markets Day took place on 19 November 2025

Our Executive Team were joined by our investors and key opinion leaders to discuss and deliver the following key items:

Our ongoing aim to power the next era of endoscopy, using our advanced technology
Q3 trading update and financial outlook for 2026
A plan to unlock the full potential of Kamaptive Technology and broaden its adoption within Gatroenterology and beyond
Presentations of clinical outcomes delivered by key opinion leaders
Demonstrations on new products in our commercial pipeline

Watch the full video

Download the Presentation Slides

Download

Performance highlights

Financial highlights

£15.7m

Revenue

£69m

Net assets

£26.5m

Cash and cash equivalents*

Speedboat Utilisation

Creo's Core Technology Growth

42%

Volume increase of procedures using Speedboat Inject vs. H2-2022

Building Partnerships

Kamaptive robotic licensing deal with Intuitive with first revenues (May 2022)

Advanced energy

Advanced energy platform with 5 matched single-use devices

People

133

Employees

13

Offices

9

Countries

Patents

318

Granted

397

Pending*

*As at 30 June 2023

The markets we address are large

We focus on significant markets where we can bring products to market that serve poorly met needs.

Our Market Focus:

Interventional gastroenterology

For the dissection, resection, ablation and haemostasis of diseased GI tissue.

Interventional pulmonology

Soft tissue Microwave ablation devices for ablationof tumours in a wide range of tissue types in the lung, stomach, oesophagus and colon.

Surgery

Our unique IP portfolio has a clear potential to meet needs in several additional lucrative markets in robotics and beyond.

Urology

Comprehensive line of Urodynamics equipment to treat conditions such as bladder cancer and incontinence.